Compare STG & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STG | IMUX |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.4M | 85.8M |
| IPO Year | 2018 | N/A |
| Metric | STG | IMUX |
|---|---|---|
| Price | $5.64 | $0.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 7.7K | ★ 1.2M |
| Earning Date | 11-20-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.01 | N/A |
| Revenue | ★ $285,589,112.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.45 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.28 | $0.56 |
| 52 Week High | $15.00 | $1.42 |
| Indicator | STG | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 44.53 | 40.71 |
| Support Level | $4.84 | $0.67 |
| Resistance Level | $5.99 | $0.73 |
| Average True Range (ATR) | 0.41 | 0.05 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 44.91 | 13.66 |
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.